Last reviewed · How we verify
NCT06758271
Special Drug Use-results Survey for Long-term Use（Avacopan）
trial testing Avacopan in Microscopic Polyangiitis (MPA) in 250 participants. Currently enrolling.
31 May 2028
Quick facts
| Lead sponsor | Kissei Pharmaceutical Co., Ltd. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 29 July 2022 |
| Primary completion | 31 May 2028 |
| Estimated completion | 31 May 2028 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Avacopan (AVACOPAN) — full drug profile →
Conditions studied
- Microscopic Polyangiitis (MPA) — all drugs for Microscopic Polyangiitis (MPA) →
- Granulomatosis With Polyangiitis (GPA) — all drugs for Granulomatosis With Polyangiitis (GPA) →
Sponsor
Kissei Pharmaceutical Co., Ltd. — full company profile →
Who can join
Eligibility, any sex, with Microscopic Polyangiitis (MPA) or Granulomatosis With Polyangiitis (GPA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06758271
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Avacopan
Trials testing the same drug.
- NCT07373262 — Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement · Phase 3 · not yet recruiting
- NCT06676579 — Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) · Phase 2 · recruiting
- NCT06321601 — Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Ye · Phase 3 · recruiting
- NCT06468826 — A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) · Phase 1 · completed
- NCT06072482 — A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis · Phase 4 · recruiting
Other Kissei Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06757257 — Special Drug Use-results Survey for Long-term Use (Fostamatinib) · recruiting
- NCT05831670 — An Early Phase 2 Clinical Study of KSP-0243 · Phase 2 · completed
- NCT05445167 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain · Phase 3 · completed
- NCT05440383 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia · Phase 3 · completed
- NCT04867551 — A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06758271 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kissei Pharmaceutical Co., Ltd.
- Last refreshed: 17 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06758271.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing